ST-148 (antiviral)

Antiviral drug targeting HIV-1

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (3S,4S)-3-[[2-(4-chlorophenyl)ethyl]amino]-4-hydroxy-1-phenylbutan-1-one | image = ST-148-AV_structure.png | image2 = }}

ST-148 is an investigational antiviral drug that has shown potential in the treatment of HIV-1, the most common and pathogenic strain of the human immunodeficiency virus. It is a small molecule that targets the HIV-1 Gag protein, which plays a crucial role in the virus's replication cycle.

Mechanism of Action

ST-148 functions by binding to the Gag protein of HIV-1. The Gag protein is essential for the assembly and maturation of the virus. By interfering with Gag, ST-148 disrupts the proper assembly of viral particles, thereby inhibiting the replication of the virus. This mechanism is distinct from other classes of antiretroviral drugs, such as reverse transcriptase inhibitors and protease inhibitors, which target different stages of the HIV life cycle.

Development and Research

Research into ST-148 has been driven by the need for new therapeutic options that can overcome resistance to existing antiretroviral drugs. Preclinical studies have demonstrated that ST-148 is effective against a broad range of HIV-1 strains, including those resistant to current therapies. The drug's unique mechanism of action makes it a promising candidate for combination therapy, potentially enhancing the efficacy of existing treatment regimens.

Clinical Trials

As of the latest updates, ST-148 is undergoing clinical trials to evaluate its safety and efficacy in humans. These trials are crucial for determining the appropriate dosing, potential side effects, and overall effectiveness of the drug in treating HIV-1 infections. The outcomes of these trials will inform future development and potential approval for clinical use.

Potential Impact

If successful, ST-148 could provide a new tool in the fight against HIV/AIDS. Its ability to target the Gag protein offers a novel approach to inhibiting viral replication, which could be particularly beneficial for patients with drug-resistant HIV strains. Additionally, ST-148 could be used in combination with other antiretrovirals to enhance treatment outcomes and reduce the likelihood of resistance development.

Related pages

• HIV/AIDS
• Antiretroviral drug
• Gag protein
• Drug resistance in HIV